GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Targeting the Vascular System

$397,281
Tracy T Batchelor · Massachusetts General Hospital · P50 · FY2015 · CA

Antagonistic role of ARF and ADAR1 in triple-negative breast cancer

$397,274
Jason Weber · Washington University · R01 · FY2024 · CA

Cell lineage as an indicator of immune response in neuroblastoma

$397,270
Rani E George · Dana-Farber Cancer Inst · R01 · FY2023 · CA

Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer

$397,192
Terence Marques Williams · Ohio State University · R01 · FY2017 · CA

TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity

$397,110
Melanie R Rutkowski · University Of Virginia · R01 · FY2024 · CA

Neutralizing Stromal NetrinG1 to Intercept Pancreatic Cancer

$397,088
Edna Cukierman · Research Inst Of Fox Chase Can Ctr · U54 · FY2024 · CA

Cancer Cell Intrinsic Interferon-I pathway Activation by Fractionated Radiation

$397,076
Sandra Demaria · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA

The Role of ADAM15 in Prostate Tumor Intravazation and Metastasis

$397,075
Mark L Day · University Of Michigan At Ann Arbor · R01 · FY2012 · CA

Mechanical Regulation of Tumor Angiogenesis

$397,073
Cynthia A Reinhart-King · Cornell University · R01 · FY2015 · HL

Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines

$397,052
Bing Xu · Brandeis University · R01 · FY2025 · CA

Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines

$397,052
Bing Xu · Brandeis University · R01 · FY2023 · CA

Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer

$396,958
Weidong Xu · Endeavor Health Clinical Operations · R01 · FY2024 · CA

Project 1: Elucidating the genetics and cell of origin of pancreatic cancer initiation

$396,921
Laura D Attardi · Stanford University · P01 · FY2024 · CA

Induction of interferon response by chromatin damaging anti-cancer therapy

$396,881
Katerina V Gurova · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA

Induction of interferon response by chromatin damaging anti-cancer therapy

$396,881
Katerina V Gurova · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA

Mechanical Regulation of Tumor Angiogenesis

$396,871
Cynthia A Reinhart-King · Cornell University · R01 · FY2016 · HL

The Role of ADAM15 in Prostate Tumor Intravazation and Metastasis

$396,866
Mark L Day · University Of Michigan At Ann Arbor · R01 · FY2011 · CA

Role of Tumor Stem Cells Recurrent Prostate Cancer

$396,862
Gary Smith · Univ Of North Carolina Chapel Hill · P01 · FY2012 · CA

Precision nanotherapeutics for cancer treatment

$396,853
Jianjun Cheng · University Of Illinois At Urbana-Champaign · R01 · FY2020 · CA

Precision nanotherapeutics for cancer treatment

$396,853
Timothy M Fan · University Of Illinois At Urbana-Champaign · R01 · FY2021 · CA

The lymph node microenvionment in tumor metastasis

$396,852
Judith A. Varner · University Of California, San Diego · R01 · FY2009 · CA

Molecular mechanism by which Tim-3 induces T cell dysfunction and inhibits anti-t

$396,839
Vijay K Kuchroo · Brigham And Women'S Hospital · P01 · FY2017 · AI

Mechanisms and therapeutic targeting of osteoimmune functions of RANKL in breast cancer

$396,834
Selvarangan Ponnazhagan · University Of Alabama At Birmingham · R01 · FY2024 · CA

Project 3: Early detection and prevention of MM progression

$396,805
Peter Leif Bergsagel · Mayo Clinic Arizona · P50 · FY2021 · CA

Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer

$396,771
Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2021 · CA